Company Overview
Anbio Biotechnology specializes in the development and commercialization of in vitro diagnostics (IVD) products, distributing these solutions across a global footprint that includes the European Union, Asia Pacific, North America, South America, Africa, and other international markets. The company operates within the Healthcare sector, specifically focusing on the Medical Instruments & Supplies industry, which implies a concentration on essential medical testing tools and diagnostic equipment used in clinical settings. With a market capitalization of $1.02B, the company commands significant valuation despite having a relatively lean operational structure supported by 27 employees. The annual revenue of $6.92M indicates a niche player within the broader diagnostic landscape, suggesting the company leverages high-value, low-volume product lines to generate substantial returns relative to its modest revenue base and small workforce.
Financial Health
The financial performance for the trailing twelve months shows revenue of $6.92M paired with a net income of $2.57M, while EBITDA data is not available for this reporting period. The substantial gap between the $6.92M in revenue and the $2.57M in net income reveals an exceptionally efficient cost structure where operating expenses are controlled to a degree that allows a significant portion of sales to flow directly to the bottom line. Although free cash flow figures are not disclosed in the available data, the presence of $13.43M in cash on the balance sheet suggests the company maintains a robust liquidity position without relying on external financing for daily operations. The gross margin stands at 89.7%, indicating that the company retains nearly nine dollars of gross profit for every ten dollars of sales, a figure typical of high-margin diagnostic reagent businesses. Furthermore, the operating margin is reported at 73.4%, and the profit margin reaches 37.2%, collectively demonstrating that the business model is highly scalable and sensitive to volume rather than volume-dependent cost drivers. Comparing the available cash of $13.43M against a debt figure that is not applicable indicates a capital structure that is entirely debt-free, eliminating interest expense burdens. The current ratio is listed at 211.10, a metric that signals an extreme level of short-term liquidity, meaning the company holds more than 200 times its current liabilities in liquid assets. Additionally, the return on equity is 11.2% and the return on assets is 4.7%, metrics that reveal management is generating modest returns on the asset base but strong returns for shareholders relative to the equity invested.
Valuation Assessment
The trailing twelve-month P/E ratio is 386.50, while the forward P/E ratio is not available; the absence of a forward P/E prevents a direct comparison regarding expected earnings trajectory but highlights the reliance on historical earnings for valuation. The price-to-book ratio is 36.93, a figure that indicates the market is pricing the company at a significant premium over its book value, likely reflecting the high intangible value of its intellectual property and diagnostic patents. The price-to-sales ratio stands at 147.08, suggesting that investors are willing to pay a very high multiple relative to sales, whereas the EV/EBITDA ratio is not available for calculation. The stock has experienced substantial volatility, with a 52-week high of $55.65 and a 52-week low of $5.89, placing the current trading environment within a wide historical range that reflects investor sentiment shifts. The beta value is not available, which precludes a specific assessment of the stock's price volatility relative to the broader market index. These valuation metrics combined with the wide trading range illustrate a stock where market expectations are detached from traditional earnings multiples, driven instead by the potential of its IVD product portfolio.
Growth & Income
Revenue growth over the last year decreased by -21.6%, while earnings growth remained positive at 2.8%, implying that the company managed to grow its bottom line even as top-line sales declined, a phenomenon often driven by margin expansion or cost reductions rather than volume increases. Since the dividend yield is not applicable and the payout ratio is 0.0%, the company does not distribute cash to shareholders and instead retains all earnings to reinvest into research, development, or market expansion. This reinvestment strategy is consistent with a firm in the diagnostic sector that requires continuous innovation to maintain its product pipeline against emerging health threats. The overall growth and income profile is characterized by a lack of dividend income but a demonstrated ability to grow earnings despite a contraction in recent revenue, highlighting a capital-efficient growth model that prioritizes internal expansion over shareholder payouts.